Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer
2016-004632-38Phase 2Completed
- Sponsor
- Národný onkologický ústav
- Start
- Aug 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in Germ Cell Testicular Cancer and extracranial germ cell tumor (EGCT), sponsored by Národný onkologický ústav. Primary endpoint: 12-week progression-free survival rate. Started Aug 2017; status: completed.
02
Drugs
avelumab
03
Conditions
Germ Cell Testicular Cancerextracranial germ cell tumor (EGCT)
Beyond the preview
Go deeper on 2016-004632-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004632-38.